Functional Indications of Sonidegib

Sonidegib, trade nameOdomzo (Sonidegib) is a Hedgehog pathway inhibitor that was approved by the U.S. Food and Drug Administration in 2015. FDA-approved for the treatment of patients with locally advanced basal cell carcinoma (laBCC) that has relapsed after surgery or radiation therapy, or for patients who are ineligible for surgery/radiation therapy. Solidagib is metabolized in the liver mainly through the action of cytochrome P450 3A (CYP3A).

Solidegib bindsSmo (a transmembrane protein), resulting in the inhibition of Hedgehog signal transduction. It helps reduce the growth of cancer cells. The recommended dose of sondecoxib is 200 mg taken orally once daily on an empty stomach. 14 Most cancer treatments produce mild to moderate adverse events, which can be controlled through dose adjustment, concomitant medication, and adequate hydration. Based on population pharmacokinetics (PKs) calculations, Solidegib is estimated to be approximately 28. Of the total absorbed dose of Solidegib, 70% is excreted in the feces and 30% is excreted in the urine.

Solidagen is a new type of drug for treating diseases. Although the original drug Solidagen has been marketed in China, it has not yet entered the scope of medical insurance, and its price has not yet been determined. The Original drug Solidaget listed overseas, European version specificationsThe price per box of 200mg*30 tablets is around RMB 46,000 (the price may fluctuate due to the exchange rate), which is relatively expensive. The ingredients of the two drugs are basically the same. There is currently no generic version of Solidaget produced and marketed. For specific prices and drug information, please consult Yaodei Medical Consultants.